Table 3 Numbers of patients treated with platinum agents for lung cancer (NSCLC and SCLC)
Age | Platainum | Toyama | Ishikawa | Fukui | Nagano | Hokushin region |
|---|---|---|---|---|---|---|
Cases (%) | Cases (%) | Cases (%) | Cases (%) | Cases (%) | ||
< 75 | Carboplatin | 91 (75.2%) | 75 (73.5%) | 43 (53.8%) | 63 (55.8%) | 272 (65.4%) |
Cisplatin | 30 (24.8%) | 27 (26.5%) | 37 (46.3%) | 50 (44.2%) | 144 (34.6%) | |
≥ 75 | Carboplatin | 48 (96.0%) | 28 (96.6%) | 11 (100%) | 30 (96.8%) | 117 (96.7%) |
Cisplatin | 2 (4.0%) * | 1 (3.4%) * | 0 (0%) * | 1 (3.2%) * | 4 (3.3%) * | |
Total | 171 | 131 | 91 | 144 | 537 | |